He Xun Cai Jing·2025-06-05 02:15Group 1 - Wantai Biological announced that its subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received approval for the nine-valent HPV vaccine, making it the first in China and the second globally, potentially altering the competitive landscape as Merck's Gardasil has seen a decline in uptake [1] - AstraZeneca announced that its drug, Infinzi, has been approved by the National Medical Products Administration of China for use in adult patients with specific limited-stage small cell lung cancer, with clinical trials showing it can extend patient survival, positioning it as the first and only immunotherapy in this category [1] - Kangfang Biotech reported progress on the incident involving its "clinical research use only" anti-tumor drug, stating that a sales representative in Chongqing forged materials to obtain drugs, which has raised concerns about the company's compliance management and may impact its brand image and market trust [1] Group 2 - BCG Biotech announced it has received a clinical trial approval notice for its shingles vaccine, aimed at adults aged 40 and above, which could enhance the company's structure and profitability if successfully launched [1] - Sinovac Biotech disclosed that its controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., plans to reduce its stake by up to 5.9892 million shares, representing no more than 3% of the total shares, with the reduction period set for three months following the announcement, which may lead to stock price volatility given the stock's over 150% increase this year [1]